• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update

    5/15/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    • Prioritization of givastomig as I-Mab's lead program positions the Company for clinical progress
    • New givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, Spain
    • Strong financial position supported by $168.6 million of cash and cash equivalents, and short-term investments as of March 31, 2025; provides runway into 2027, through expected clinical readouts for givastomig

    ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three months ended March 31, 2025, and highlighted recent pipeline progress and business updates.

    "2025 is off to a strong start for I-Mab. Designation of givastomig as our lead program has enabled us to unlock significant value for the Company by considerably accelerating our Phase 1b program, as we work to improve the care of patients with gastric cancers, which impact more than 250,000 people globally," said Sean Fu, PhD, Chief Executive Officer of I-Mab. "Driven by study momentum and investigator interest, we have completed patient enrollment in the first of two Phase 1b dose expansion cohorts ahead of schedule. We expect to share data on both cohorts in 1H 2026. We believe the combination of significant progress in our givastomig program, substantial cash balance, streamlined operations, and new U.S.-based business model positions I-Mab to deliver for both patients and our investors."

    Pipeline Overview and Anticipated Upcoming Milestones

    Upcoming anticipated milestones for givastomig (CLDN18.2 x 4-1BB bispecific), prioritized to be I-Mab's lead program in January 2025:

    • July 2025: Presentation of new givastomig dose escalation combination data on U.S. patients at the European Society of Medical Oncology ("ESMO") Gastrointestinal ("GI") Cancers Congress 2025, being held July 2-5 in Barcelona, Spain



      Details of the ESMO GI Mini Oral Presentation:



      Title: Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)

      Speaker: Samuel J. Klempner, MD, Associate Professor of Medicine, Massachusetts General Hospital

      Presentation Number: 388MO

      Date and Time: Wednesday, July 2nd at 16:50 CEST (10:50am EST)
    • 1H 2026: Presentation of data from givastomig dose expansion cohorts (n=40)

    Enrollment in the ongoing dose expansion study for givastomig is progressing ahead of schedule. In addition, the Company anticipates updates in 2026 for two programs being developed with its partners: uliledlimab (monoclonal antibody targeting CD73); and ragistomig (PD-L1 x 4-1BB bispecific).

    First Quarter 2025 Financial Results – In connection with the divestiture of its Greater China assets and business operations, I-Mab's first quarter 2024 amounts have been recast to conform to the discontinued operations presentation. Additionally, certain non-recurring costs occurred during the first quarter of 2024 that impact quarter-over-quarter comparisons.

    Cash Position

    As of March 31, 2025, the Company had cash and cash equivalents, and short-term investments of $168.6 million. The Company's current cash position is expected to fund the givastomig Phase 1b study through anticipated dose expansion data readouts and further development initiatives into 2027.

    Shares Outstanding

    As of March 31, 2025, the Company had 187,818,796 ordinary shares issued and outstanding, representing the equivalent of 81,660,346 ADSs, assuming the conversion of all ordinary shares into ADSs.

    Research and Development Expenses

    Research and development expenses were $0.8 million for the three months ended March 31, 2025, compared to $6.1 million for the three months ended March 31, 2024. The decrease was primarily driven by reimbursements recognized under an existing collaboration agreement and lower contract research organization costs during the three months ended March 31, 2025.

    Administrative Expenses

    Administrative expenses were $4.5 million for the three months ended March 31, 2025, compared to $2.4 million for the three months ended March 31, 2024. Employee share-based compensation expenses during the three months ended March 31, 2024 were $4.8 million lower, primarily driven by forfeitures in connection with the divestiture of the Greater China assets and business operations. Additionally, legal expenses were $2.5 million lower during the three months ended March 31, 2025.

    Interest Income

    Interest income was $1.9 million for the three months ended March 31, 2025, compared to $0.7 million for the three months ended March 31, 2024. The increase was primarily attributable to higher interest rates earned on cash balances in 2025.

    Other Income (Expenses), Net

    Other income (expenses), net were $0.2 million for the three months ended March 31, 2025, compared to $(0.6) million for the three months ended March 31, 2024.

    Equity in Loss of Affiliates

    Equity in loss of affiliates was $1.0 million for the three months ended March 31, 2024 due to recognition of the employee stock ownership plan expenses from the Company's unconsolidated investee as a result of the divestiture of the Greater China assets and business operations. There was no equity in loss of affiliates for the three months ended March 31, 2025.

    Net Loss from Continuing Operations

    Net loss from continuing operations was $(3.2) million for the three months ended March 31, 2025, compared to $(9.4) million for the three months ended March 31, 2024. Net loss from continuing operations per share attributable to ordinary shareholders was $(0.02) for the three months ended March 31, 2025, compared to $(0.05) for the three months ended March 31, 2024.

    Net Loss from Discontinued Operations

    On April 2, 2024, the Company closed the China divestiture announced on February 7, 2024 (the "Transaction"). In accordance with ASC 205-20, the Company determined that the Transaction represented a strategic shift that had a major effect on the business and therefore, met the criteria for classification as discontinued operations. As a result, the Company recognized a loss from discontinued operations of $6.9 million for the three months ended March 31, 2024.

    Net Loss

    Net loss was $(3.2) million for the three months ended March 31, 2025, compared to $(16.3) million for the three months ended March 31, 2024. Net loss per share attributable to ordinary shareholders was $(0.02) for the three months ended March 31, 2025, compared to $(0.09) for the three months ended March 31, 2024.

    About Givastomig

    Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 ("CLDN18.2")-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line ("1L") metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.

    The ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data.

    Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.

    About I-Mab

    I-Mab (NASDAQ:IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

    I-Mab Forward Looking Statements

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plans", "potential", "estimates", "confident", and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the Company's expectations regarding its cash runway; the timing and progress of studies and trials (including with respect to the patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

    I-Mab Investor & Media Contacts

    PJ Kelleher

    LifeSci Advisors

    +1-617-430-7579

    [email protected]

    [email protected]

     
    I-Mab
    Consolidated Balance Sheets
    (Unaudited; All amounts in thousands, except for par value and share data)
           
      As of March 31,  As of December 31, 
      2025  2024 
    Assets      
    Current assets      
    Cash and cash equivalents $53,597  $68,263 
    Short-term investments  115,025   105,135 
    Prepayments and other receivables  4,611   3,295 
    Total current assets  173,233   176,693 
    Property, equipment and software  188   201 
    Operating lease right-of-use assets  3,404   3,597 
    Investments at fair value, available-for-sale debt securities (amortized cost of $38,727)  30,824   30,824 
    Other non-current assets  1,292   1,365 
    Total assets $208,941  $212,680 
           
    Liabilities and shareholders' equity      
    Current liabilities      
    Accruals and other payables $6,916  $7,638 
    Operating lease liabilities, current  835   816 
    Total current liabilities  7,751   8,454 
    Operating lease liabilities, non-current  2,849   3,066 
    Total liabilities  10,600   11,520 
           
    Shareholders' equity      
    Ordinary shares ($0.0001 par value, 800,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 187,818,796 and 187,452,495 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively)  19   19 
    Treasury stock  (5,881)  (6,225)
    Additional paid-in capital  1,460,005   1,460,021 
    Accumulated other comprehensive income  33,387   33,384 
    Accumulated deficit  (1,289,189)  (1,286,039)
    Total shareholders' equity  198,341   201,160 
    Total liabilities and shareholders' equity $208,941  $212,680 
             



    I-Mab
    Consolidated Statements of Comprehensive Loss
    (Unaudited; All amounts in thousands, except for share and per share data)
        
      Three Months Ended March 31, 
      2025  2024 
    Revenues      
    Licensing and collaboration revenue $—  $— 
    Total revenues  —   — 
    Expenses      
    Research and development expenses(1)  (777)  (6,062)
    Administrative expenses(2)  (4,489)  (2,441)
    Total expenses  (5,266)  (8,503)
    Loss from operations  (5,266)  (8,503)
    Interest income  1,872   709 
    Other income (expenses), net  244   (587)
    Equity in loss of affiliates(3)  —   (1,038)
    Loss from continuing operations before income tax expense  (3,150)  (9,419)
    Income tax expense  —   — 
    Loss from continuing operations  (3,150)  (9,419)
           
    Discontinued operations:      
    Loss from operations of discontinued operations(4)  —   (6,898)
    Income tax expense  —   — 
    Loss from discontinued operations  —   (6,898)
           
    Net loss  (3,150)  (16,317)
           
    Other comprehensive income (loss):      
    Foreign currency translation adjustments, net of tax  3   1,025 
    Total comprehensive loss $(3,147) $(15,292)
            
    Weighted-average number of ordinary shares used in calculating net loss per share - basic and diluted  187,679,483   185,858,408 
    Net loss from continuing operations per share - basic and diluted $(0.02) $(0.05)
    Net loss from discontinued operations per share - basic and diluted $—  $(0.04)
    Net loss per share - basic and diluted $(0.02) $(0.09)
           
    Net loss from continuing operations per ADS(5) - basic and diluted $(0.04) $(0.12)
    Net loss from discontinued operations per ADS(5) - basic and diluted $—  $(0.09)
    Net loss per ADS(5) - basic and diluted $(0.04) $(0.21)
             

    (1) Includes share-based compensation expense of $0.1 million and $0.3 million for the three months ended March 31, 2025 and 2024, respectively.

    (2) Includes share-based compensation expense of $0.2 million and $(4.5) million for the three months ended March 31, 2025 and 2024, respectively. The three months ended March 31, 2024 includes forfeitures as a result of divestiture of the Greater China assets and business operations and organizational changes.

    (3) Includes share-based compensation expense of $(0.7) million for the three months ended March 31, 2024, which includes forfeitures as a result of divestiture of the Greater China assets and business operations.

    (4) Includes share-based compensation expense of $(11.6) million for the three months ended March 31, 2024, which includes forfeitures as a result of divestiture of the Greater China assets and business operations.

    (5) Each 10 ADSs represents 23 ordinary shares.



    Primary Logo

    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

      Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congre

      7/2/25 11:15:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

      Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research, a journal of the American Association for Cancer Research (CCR), and a highly-ranked clinical oncology publication. The CCR paper1 details promising clinical data showing that giva

      6/30/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

      71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of ESMO Gastrointestinal Cancers Congress 2025 (ESMO

      6/26/25 6:30:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

      Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

      1/6/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Third Quarter 2024 Results

      Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

      11/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      7/2/25 11:18:19 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      6/26/25 6:30:04 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      6/12/25 7:05:03 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/13/24 11:26:50 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/9/24 4:01:20 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by I-MAB

      SC 13D - I-Mab (0001778016) (Subject)

      12/1/23 2:41:06 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care